Comprehensive Psychiatry
Volume 45, Issue 3 , Pages 161-167 , May 2004

Ethical use of long-acting medications in the treatment of severe and persistent mental illnesses

  • Laura Weiss Roberts

      Affiliations

    • Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
    • Corresponding Author InformationAddress reprint requests to Laura Weiss Roberts, M.D., Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA
    • ,
  • Cynthia M.A Geppert

      Affiliations

    • Department of Psychiatry, University of New Mexico School of Medicine, Albuquerque, NM, USA

References 

  1. National Institute of Mental Health. The Numbers Count: Mental Disorders in America. http://www.nimh.nih.gov/publicat/numbers.cfm, Accessed 2/26/04.
  2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders Text Revision. Arlington, VA: American Psychiatric Press; 2000;
  3. Crisp AH, Gelder MG, Rix S, Meltzer HI, Rowlands OJ. Stigmatisation of people with mental illnesses. Br J Psychiatry. 2000;177:4–7
  4. Ostman M, Kjellin L. Stigma by association (psychological factors in relatives of people with mental illness). Br J Psychiatry. 2002;181:494–498
  5. Whooley MA, Kiefe CI, Chesney MA, Markovitz JH, Matthews K, Hulley SB. Depressive symptoms, unemployment, and loss of income (the CARDIA study). Arch Intern Med. 2002;162:2614–2620
  6. Department of Health and Human Services . Mental Health (A Report of the Surgeon General). Rockville, MD: DHHS; 1999;
  7. Murray JL, Lopez AD. The Global Burden of Disease. A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard School of Public Health; 1996;
  8. Department of Health and Human Services . Mental Health; Culture, Race, Ethnicity Supplement to Mental Health (A Report of the Surgeon General). Rockville, MD: DHHS; 2000;
  9. Service US Public Health Service . The Surgeon General’s Call to Action to Prevent Suicide. Washington, DC: DHHS; 1999;
  10. US Department of Health and Human Services . Report of the Surgeon General’s Conference on Children’s Mental Health (A National Action Agenda). Washington, DC: DHHS; 2000;
  11. Lehman AF, Steinwachs DM. Translating research into practice (the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations). Schizophr Bull. 1998;24:1–10
  12. Buckley PF. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry. 2001;50:912–924
  13. Dawkins K, Lieberman JA, Lebowitz BD, Hsiao JK. Antipsychotics: past and future: National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998. Schizophr Bull. 1999;25:395–405
  14. Kelleher JP, Centorrino F, Albert MJ, Baldessarini RJ. Advances in atypical antipsychotics for the treatment of schizophrenia (new formulations and new agents). CNS Drugs. 2002;16:249–261
  15. Frishman WH, Sherman D, Feinfeld DA. Innovative drug delivery systems in cardiovascular medicine (nifedipine-GITS and clonidine-TTS). Cardiol Clin. 1987;5:703–716
  16. Diener HC, Limmroth V. Acute management of migraine (triptans and beyond). Curr Opin Neurol. 1999;12:261–267
  17. Gerich JE. Novel insulins (expanding options in diabetes management). Am J Med. 2002;113:308–316
  18. Kaunitz AM. Long-acting contraceptive options. Int J Fertil Menopausal Stud. 1996;41:69–76
  19. Love RC. Strategies for increasing treatment compliance (the role of long-acting antipsychotics). Am J Health Syst Pharm. 2002;59(Suppl 8):S10–15
  20. Shen WW. The need for depot atypical antipsychotics in the U.S. Psychiatr Serv. 1998;49:727
  21. Wiles DH, McCreadie RG, Whitehead A. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. Psychopharmacology (Berl). 1990;101:274–281
  22. Levron JC, Ropert R. Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics. Encephale. 1987;13:83–87
  23. Simon RI. Clinical Psychiatry and the Law. Washington, DC: American Psychiatric Press; 1992;
  24. Eastwood N, Pugh R. Long-term medication in depot clinics and patients’ rights (an issue for assertive outreach). Psychiatr Bull. 1997;21:273–275
  25. Benkert O, Graf-Morgenstern M, Hillert A, Sandmann J, Ehmig SC, Weissbecker H, et al.  Public opinion on psychotropic drugs (an analysis of the factors influencing acceptance or rejection). J Nerv Ment Dis. 1997;185:151–158
  26. Dain N. Reflections on antipsychiatry and stigma in the history of American psychiatry. Hosp Commun Psychiatry. 1994;45:1010–1014
  27. Balon R. The underutilization of depot neuroleptic therapy. J Clin Psychiatry. 1994;55:39; [letter]
  28. Glazer WM, Kane JM. Depot neuroleptic therapy (an underutilized treatment option). J Clin Psychiatry. 1992;53:426–433
  29. Dencker SJ. Depot neuroleptics (a Scandinavian view). Acta Psychiatr Belg. 1981;81:115–120
  30. Svedberg B, Hallstrom T, Lutzen K. The morality of treating patients with depot neuroleptics (the experience of community psychiatric nurses). Nurs Ethics. 2000;7:35–46
  31. Svedberg B, Lutzen K. Psychiatric nurses’ attitudes towards patient autonomy in depot clinics. J Adv Nurs. 2001;35:607–615
  32. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:290–299
  33. Roberts LW. Informed consent and clinical care for mental illness. In:  Smelser NJ,  Balles PB editor. International Encyclopedia of the Social and Behavioral Sciences. Oxford, UK: Elsevier; 2001;p. 12296–12302
  34. Roberts LW. Informed consent and the capacity for voluntarism. Am J Psychiatry. 2002;159:705–712
  35. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. New York, NY: Oxford University Press; 2001;
  36. Faden Ruth R, Beauchamp TL. A History and Theory of Informed Consent. New York, NY: Oxford University Press; 1986;
  37. Bunn MH, O’Connor AM, Tansey MS, Jones BD, Stinson LE. Characteristics of clients with schizophrenia who express certainty or uncertainty about continuing treatment with depot neuroleptic medication. Arch Psychiatr Nurs. 1997;11:238–248
  38. Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand. 1997;95:464–468
  39. Trenckmann U. Effects and side effects of depot neuroleptics as perceived by patients. Psychiatr Prax. 1990;17:184–187
  40. Walburn J, Gray R, Gournay K, Quraishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry. 2001;179:300–307
  41. Larsen EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand. 1996;93:381–388
  42. Hoencamp E, Knegtering H, Kooy JJS. Patient requests and attitudes towads neuroleptics. Nord J Psychiatry. 1995;49(Suppl 35):47–55
  43. Jacobsson L, Odling H. Psychological aspects of depot treatment of schizophrenic syndromes. Lakartidningen. 1980;7740:3522–3526
  44. Desai NM, Huq Z, Martin SD, McDonald G. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The Schizophrenia Treatment & Assessment Group. Adv Ther. 1999;16:78–88
  45. Pan PC, Tantam D. Clinical characteristics, health beliefs and compliance with maintenance treatment (a comparison between regular and irregular attenders at a depot clinic). Acta Psychiatr Scand. 1989;79:564–570
  46. Buis W. Patients’ opinions concerning side effects of depot neuroleptics. Am J Psychiatry. 1992;149:844–845
  47. Muir-Cochrane EC. The role of the community mental health nurse in the administration of depot neuroleptic medication (‘not just the needle nurse!’). Int J Nurs Pract. 1998;4:254–260
  48. Vedantam S. In: Long-term drugs may assist schizophrenics. Washngton, DC: The Washington Post; 2002;p. 40A
  49. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in “revolving door” schizophrenic patients. J Clin Psychiatry. 1996;57:337–345
  50. Knapp M, Ilson S, David A. Depot antipsychotic preparations in schizophrenia (the state of the economic evidence). Int Clin Psychopharmacol. 2002;17:135–140
  51. Swartz MS, Swanson JW, Wagner HR, Burns BJ, Hiday VA. Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness. J Nerv Ment Dis. 2001;189:583–592
  52. Gerlach J. Depot neuroleptics in relapse prevention (advantages and disadvantages). Int Clin Psychopharmacol. 1995;9(Suppl 5):17–20
  53. Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf. 1994;10:464–479
  54. Marder SR, Davis JM, Erehefsky L, Fleischhacker W, Kane JM, Schooler NR. Partial-compliance; the need for long-acting antipsychotic. The Journal of Clinical Psychiatry Audiograph Series. Memphis, TN: Physicians Postgraduate Press; 2002;
  55. Cookson JC. Side effects during long-term treatment with depot antipsychotic medication. Clin Neuropharmacol. 1991;14(Suppl 2):S24–S30
  56. Linszen D, Dingemans P, Lenior M. Early intervention and a five year follow up in young adults with a short duration of untreated psychosis (ethical implications). Schizophr Res. 2001;51:55–61
  57. Sheitman BB, Lieberman JA. The natural history and pathophysiology of treatment resistant schizophrenia. J Psychiatr Res. 1998;32:143–150
  58. Garavan J, Browne S, Gervin M, Lane A, Larkin C, O’Callaghan E. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry. 1998;39:215–219
  59. Kessler RC, Berglund PA, Bruce ML, Koch JR, Laska EM, Leaf PJ, et al.  The prevalence and correlates of untreated serious mental illness. Health Serv Res. 2001;36:987–1007
  60. Dickey B. Review of programs for persons who are homeless and mentally ill. Harv Rev Psychiatry. 2000;8:242–250
  61. Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry. 2001;62:545–551
  62. Anderson D, Leadbetter A, Williams B. In defence of the depot clinic. The consumer’s opinion. Psychiatr Bull. 1989;13:177–179

☆ Supported by National Institute of Mental Health (K02MH01918-03) and National Institute on Drug Abuse (R01DA13139-03) grants to L.W.R.

PII: S0010-440X(04)00018-5

doi: 10.1016/j.comppsych.2004.02.003

Comprehensive Psychiatry
Volume 45, Issue 3 , Pages 161-167 , May 2004

Article Tools